Heartflow, Inc.
HTFLHeartflow is a medical technology company providing an AI-powered software platform for the non-invasive diagnosis and management of coronary artery disease (CAD).
Earnings
Next report
Nov 11, 2026 (in 2 months)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Heartflow is a medical technology company providing an AI-powered software platform for the non-invasive diagnosis and management of coronary artery disease (CAD). The company leverages deep learning and computational fluid dynamics to create personalized 3D models of a patient's heart from standard CCTA scans, delivering actionable insights on blood flow and plaque composition. Its core value proposition is reducing the need for invasive procedures while improving the accuracy of CAD detection compared to traditional stress-based testing.
Heartflow is a leading provider of AI-powered CAD testing, with its flagship FFRCT product representing the vast majority of its revenue and holding significant clinical validation through major trials.
FAQ
- What is Heartflow, Inc.'s market cap?
- Heartflow, Inc. (HTFL) has a market capitalization of $4.2B and trades on NASDAQ.
- What is Heartflow, Inc.'s revenue and profitability?
- Heartflow, Inc. generated $212.1M in trailing twelve-month revenue with a net loss of $118.4M, representing a net margin of -55.8%. Gross margin stands at 80.1%, with free cash flow of -$59.2M. The latest reported period is Q2 2026.
- Who are Heartflow, Inc.'s competitors?
- Heartflow, Inc.'s key competitors include GE HealthCare, Heartbeam, Inc. Common Stock, Boston Scientific Corp., and others. These companies compete in similar markets and product categories.
- Who does Heartflow, Inc. partner with?
- Heartflow, Inc.'s notable partners include American Heart Association, American College of Cardiology.
- Where is Heartflow, Inc. headquartered?
- Heartflow, Inc. is headquartered in United States of America. It has been publicly traded since 2025.
